Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 12, 2016
Boasting a price of $44.17, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) traded -0.99% lower on the day. With the last stock price close down -15.75% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Teva Pharmaceutical Industries Ltd (ADR) has recorded a 50-day average of $49.57 and a two hundred day average of $52.37. Trading volume was down over the average, with 4,586,576 shares of TEVA changing hands under the typical 6,393,850
Zacks Investment Research has downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to Sell in a statement released on 10/12/2016.
Recent Performance Chart
Teva Pharmaceutical Industries Ltd (ADR) has one year low of $44.00 and a one year high of $66.55 with a P/E ratio of 29.47 and has a market cap of $0.
A total of 22 equity analysts have released a research note on TEVA. 10 brokerages rating the stock a strong buy, 9 firms rating the stock a buy, 6 equity analysts rating the company a hold, zero brokerages rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $72.82.
Brief Synopsis On Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.